Core Insights - The National Healthcare Security Administration has officially issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)" which marks a new phase of standardized, regulated, and digital collaborative development in China's pathology medical services [1][2] Group 1: Policy Overview - The guidelines consolidate existing pathology medical service pricing projects into 28 core items, 3 additional charge items, and 2 expansion items, creating a clearer pricing framework [2] - The National Healthcare Security Administration will guide provinces to establish a unified price benchmark, allowing regions to adjust actual execution prices based on this benchmark [2] Group 2: Digital Transformation - The policy emphasizes the application value of digital technology in pathology diagnosis, supporting the promotion of new service models such as digital slides, remote diagnosis, and intelligent analysis [3] - This shift is expected to accelerate the transition of pathology from traditional manual operations to a fully digital process, making pathology data an important "data asset" in medical services [3] Group 3: Beneficiary Companies - Companies like Anbiping, which has automated workstations for specimen processing and supports digital slide applications, are well-positioned to benefit from this policy [4] - Aide Biology focuses on precision medical conditions and has developed an automated reporting and data management system, enhancing its capabilities in pathology services [4] - Zhongyuan Qihua provides comprehensive solutions for major diseases, integrating equipment, reagents, and services to support clinical medical institutions [4] - Maike Biology specializes in providing reagents, equipment, and technical support for pathology diagnosis, aiming for automation and intelligence in laboratory processes [4] - Other companies in the ICL category include Jinyu Medical, Dean Diagnostics, Lanwei Medical, and Aide Kang, which are also expected to benefit from the policy [4]

第67届美国血液学会年会（ASH 2025）于12月6日至9日在美国奥兰多顺利落下帷幕。作为全球血液学 领域最具影响力的学术盛会之一，ASH汇聚了来自世界各地的专家学者、创新企业与临床工作者，共同 探讨血液疾病的前沿科学、临床诊疗与技术突破。 康圣环球集团作为深耕血液专科诊断二十余年的中国领先特检集团，再次亮相国际舞台，于1181号展台 与全球同行进行了深入而富有成效的交流，全面展示了我们在血液肿瘤精准诊断、伴随诊断合作、中心 实验室服务及前沿技术研发方面的综合实力。 一、 现场直击：汇聚全球目光，交流热烈纷呈 会议期间，康圣环球展台吸引了大量国际访客驻足交流，气氛热烈。我们与来自北美、欧洲、亚洲等多 地的顶尖专家学者、药企研发负责人、生物科技公司及CRO机构代表，就CAR-T治疗优化、CRISPR基 因编辑应用、MRD（微小残留病灶）监测、血液肿瘤分子诊断标准化等热点议题展开了深度对话。 二、 业务聚焦：专业平台与技术服务的全球呈现 海希生物：聚焦血液肿瘤分子诊断 旗下专业技术平台——海希生物，重点展示了其在融合基因检测、靶向基因Panel及自动化生物信息分 析等方面的完整产品体系。通过工具化、标准化、自动 ...

阿尔茨海默病不是"绝症"，医学领域已在早筛、治疗上实现突破，正逐步将其推向"可防可治"的慢性病 行列。 每年的9月，是"世界阿尔茨海默病月"，9月21日则被定为"世界阿尔茨海默病日"。在人口老龄化加剧的 当下，它不再是"老年人专属"，越来越多的50岁~60岁的人群，也已出现病理改变的迹象。然而，公众 对它的认知仍停留在"绝症""无药可治"的误区。 上海交通大学附属第六人民医院老年医学科郭起浩教授告诉第一财经，Aβ阳性是阿尔茨海默病的病理 改变核心前提，但病理改变可能比症状出现早20年：有人50岁时检测出Aβ阳性，却可能到70岁才出现 记忆下降，甚至因其他疾病去世，最终未被确诊为阿尔茨海默病。 事实上，医学领域早已在早筛、治疗上实现突破，正逐步将其推向"可防可治"的慢性病行列。 记忆消逝的背后 阿尔茨海默病（Alzheimer's disease，AD，俗称老年痴呆），是一种以脑内β-淀粉样蛋白（Aβ）沉积和 tau蛋白异常磷酸化为特征的神经退行性疾病。它最显著的表现是记忆力下降，同时常伴随语言障碍、 定向力减退、判断力和执行功能受损，以及情绪异常、行为紊乱等症状。随着病程进展，患者可能出现 生活自理能力丧失、 ...